Pandemic Protection

Sub-Fund 1
Currently taking investments for first close $120m.  Final close $300m.
SCROLL DOWN

This Sub-Fund invests in highly advanced enabling technologies prioritising those that are highly effective in pandemic protection, but have everyday relevance to improving the environment and world health. Thereby, the value of the investments will not rely on future pandemic events, and will deliver value by providing everyday global healthcare solutions, in addition to pandemic protection.

Vector Innovation Fund (VIF)’s objective is to target USD$300M for venture-growth investments in Pandemic Protection and global healthcare companies primarily in Europe, UK and North America with significant Intellectual Property (IP) and with an ability to expand internationally.

Investment Criteria

The investment criteria for the Pandemic Protection Sub-Fund is:

  • Impact technologies that solve current and future challenges
  • Protection of health and our environments using enabling technologies
  • Future proofing and eradication of some of our global healthcare challenges
  • Health risk assessment, monitoring and analysis for contact and travel
  • Identifying international companies that operate in stable geographic locations

The Pandemic Protection Fund focuses on technologies that are close toor have reached a commercial inflection point. These target companies will be either early stage or building towards international commercial success. They must have global ambitions and the ability to disrupt their market. Such disruption comes with risk but our enabling tech investment advisory team will only promote companies able to demonstrate absolute understanding ofthe market and how to penetrate it.

Successful companies will be developing the technology, intellectual property and world-class team it takes to succeed – they will be extraordinary technologies and teams able to transform their sectors.

Pandemic Impact

COVID-19 affected world healthcare and prosperity far more than anyone imagined, and many sufferers may have legacy heart damage, blood clotting and immune response complications. It is becoming clear the pandemic will have medium to long-term health implications for significant numbers of patients, whether they had a severe infection or were asymptomatic.

‘COVID-19 Syndrome’ or ‘Long-Form COVID’ are terms being used to capture the multiple future health challenges resulting from the initial infection.

This pandemic is just one in a series, including SARs, Ebola and Zika, with more forecast to follow, while established international health challenges such as obesity and antibiotic resistance set to continue.

Fund Size
Expected targeted commitments totalling $300m
First close: $120m
Final close: $300m
Final close expected 19 months after first close
General Partners
Vector Innovation GP S.à.r.l.
Fund
Vector Innovation Fund (Pandemic Protection Sub-Fund 1) SCA SICAV RAIF Luxembourg SCA
Target Sectors
Nanotechnology
AI/Machine learning
Biotechnology
Medical devices/diagnostics
Target Regions
EU, UK, North America
Target Stages
Venture, mid-to-high growth, and expansion stage
Key Value Add
Internationally disruptive innovation companies, ripe for commercialisation, acceleration and scale-up
Deal Ticket Size
Entry tickets $5m – $10m, up to $40m over the deal term
Limited Partners (LPs) co-invest/follow-on rights acceptable
Portfolio
circa. 10-12 diversified investments
Target Returns
4.0x MOIC, 25-30% Gross IRR
Structure
Reserved Alternative Investment Fund (RAIF), A société d’investissement à capital variable (SICAV)
Fund Duration
10 years +1 +1
Fees
2% on committed / invested capital
Carried Interest
20% subject to 8% hurdle
GP Commitment
Up to 2% of committed capital

Request Further Information

Find out more detailed information about Vector Innovation Fund from our Investment Presentation and PPM Offering Document.

Request Documents >
Enabling Technologies >
Sub-Fund Launches In The future
Future Healthcare >
Sub-Fund Launches In The future

Latest News

Learn More >

About Us

Learn More >

Contact Us

Get In Touch >